Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07097571 for Adhesive Capsulitis of the Shoulder, Suprascapular Nerve Block is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Istanbul University - CerrahpasaSuprascapular Nerve Block in the Management of Patients Diagnosed With Adhesive Capsulitis 70 Exercise-Based
Clinical Trial NCT07097571 is an interventional study for Adhesive Capsulitis of the Shoulder, Suprascapular Nerve Block that is active, not recruiting. It started on February 26, 2025 with plans to enroll 70 participants. Led by Istanbul University - Cerrahpasa, it is expected to complete by August 26, 2026. The latest data from ClinicalTrials.gov was last updated on July 31, 2025.
Brief Summary
This study aims to compare the efficacy of different suprascapular nerve block techniques in patients diagnosed with adhesive capsulitis.
Adhesive capsulitis, commonly known as frozen shoulder, is a condition characterized by pain and restricted range of motion in the shoulder joint, significantly affecting quality of life. The suprascapular nerve provides sensory innervation to the shoulder joint; therefore, nerve ...
Show MoreOfficial Title
Comparison of the Efficacy of Proximal and Distal Suprascapular Nerve Blocks Under Ultrasound Guidance in the Treatment of Patients Diagnosed With Adhesive Capsulitis
Conditions
Adhesive Capsulitis of the ShoulderSuprascapular Nerve BlockPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- IstanbulUC-MAvsar-01
NCT ID Number
Start Date (Actual)
2025-02-26
Last Update Posted
2025-07-31
Completion Date (Estimated)
2026-08-26
Enrollment (Estimated)
70
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Double
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Active ComparatorPatients Receiving Suprascapular Nerve Block at the Suprascapular Notch | Glenohumeral Joint Injection and Suprascapular Nerve Block An intra-articular injection into the glenohumeral joint will be performed using 4 cc of normal saline and 1 cc of betamethasone. Additionally, a suprascapular nerve block will be administered with 5 cc of lidocaine(%2). |
Active ComparatorPatients Receiving Suprascapular Nerve Block at the Spinoglenoid Notch | Glenohumeral Joint Injection and Suprascapular Nerve Block An intra-articular injection into the glenohumeral joint will be performed using 4 cc of normal saline and 1 cc of betamethasone. Additionally, a suprascapular nerve block will be administered with 5 cc of lidocaine(%2). |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Evaluation of the Strength of Shoulder External Rotation and Abduction. | Shoulder external rotation strength will be assessed in two different positions: with the arm at the side of the body and with the shoulder in 90 degrees of abduction. Additionally, shoulder abduction strength will be evaluated in two positions: with the shoulder in 90 degrees of abduction and in 90 degrees of abduction combined with 30 degrees of horizontal adduction. | Patients will be assessed at baseline (pre-procedure), 1 week, and 1 month following the glenohumeral joint injection and suprascapular nerve block |
Pain Relief | Pain will be assessed using the Numerical Rating Scale (NRS), which ranges from 0 (no pain) to 10 (worst pain imaginable), at rest, during movement, at night, and overall, both before and after injections into the glenohumeral joint and suprascapular nerve block. Higher scores indicate worse pain outcomes. | Patients will be evaluated before the glenohumeral joint injection and suprascapular nerve block, as well as 1 hour, 1 week, and 1 month after the procedure. |
Passive and Active Range of Motion of Shoulder | The shoulder joint's active and passive range of motion will be measured with a goniometer | Patients will be assessed at baseline (pre-procedure), and at 1 hour, 1 week, and 1 month following the glenohumeral joint injection and suprascapular nerve block. |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
The Numeric Rating Scale (NRS) | A pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable | Assessments were performed before, 1 hour after, 1 week after, and 1 month after the glenohumeral joint injection and suprascapular nerve block. |
Modified Constant Murley Score | Patients will be assessed according to the modified Constant score, focusing on pain, activities of daily living, range of motion, and muscle strength. | Assessments were performed before, 1 week after, and 1 month after the glenohumeral joint injection and suprascapular nerve block. |
Shoulder Disability Questionnaire | Patients will respond to the items of the Shoulder Disability Questionnaire with reference to the past 24 hours. | Assessments were performed before, 1 week after, and 1 month after the glenohumeral joint injection and suprascapular nerve block. |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
35 Years
Eligible Sexes
All
- Patients who have had shoulder pain, restricted range of motion (ROM), and night pain for at least 4 weeks
- Age younger than 35 years or older than 75 years.
- Known allergy to the agents used for injection.
- History of trauma and/or surgery involving the same shoulder.
- Presence of uncontrolled diabetes mellitus and/or hypertension.
- Presence of severe chronic respiratory disease.
- Presence of severe heart failure.
- Administration of intra- or peri-articular steroid injection to the affected shoulder within the past 2 months.
- Radiographic evidence of calcific tendinitis, glenohumeral osteoarthritis, acromioclavicular joint osteoarthritis, or bone fracture.
- Full-thickness rotator cuff tear detected by shoulder ultrasonography.
- History of surgical intervention or recent/past fracture in the ipsilateral upper extremity.
- Presence of complex regional pain syndrome or vascular disease in the ipsilateral extremity.
- Known coagulation disorders.
- Cervical disc pathology causing radiculopathy.
- Presence of inflammatory or malignant diseases.
- History of cerebrovascular disease.
- Presence of mental impairment or severe psychiatric disorders.
- Pregnancy.
Istanbul University - Cerrahpasa174 active studies to exploreStudy Responsible Party
MUSA AVŞAR, Principal Investigator, medical doctor, Istanbul University - Cerrahpasa
No contact data.
1 Study Locations in 1 Countries
Istanbul University - Cerrahpasa, Istanbul, Turkey (Türkiye)